NASDAQ:AVRO

AVROBIO Competitors

$14.00

-0.03 (-0.21 %)

(As of 11/25/2020 12:00 AM ET)

Add

Compare

Today's Range

$13.84

Now: $14.00▼

$14.33

50-Day Range

$13.72

MA: $15.43▼

$17.10

52-Week Range

$9.76

Now: $14.00▼

$29.32

Volume375,022 shs

Average Volume292,154 shs

Market Capitalization$510.31 million

P/E RatioN/A

Dividend YieldN/A

Beta1.63

AVROBIO (NASDAQ:AVRO) Vs. EDIT, SRNE, MESO, ATRA, SRRK, and CRTX

Should you be buying AVRO stock or one of its competitors? Companies in the industry of "biological products, except diagnostic" are considered alternatives and competitors to AVROBIO, including Editas Medicine (EDIT), Sorrento Therapeutics (SRNE), Mesoblast (MESO), Atara Biotherapeutics (ATRA), Scholar Rock (SRRK), and Cortexyme (CRTX).

AVROBIO vs. Editas Medicine Stock

Editas Medicine (NASDAQ:EDIT) and AVROBIO (NASDAQ:AVRO) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, analyst recommendations, institutional ownership, earnings and dividends.

Profitability

This table compares Editas Medicine and AVROBIO's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Editas Medicine	-99.62%	-26.74%	-16.38%
AVROBIO	N/A	-51.33%	-47.65%

Valuation and Earnings

This table compares Editas Medicine and AVROBIO's top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Editas Medicine	$20.53 million	89.42	$-133,750,000.00	($2.68)	-10.99
AVROBIO	N/A	N/A	$-72,960,000.00	($2.66)	-5.26

AVROBIO has lower revenue, but higher earnings than Editas Medicine. Editas Medicine is trading at a lower price-to-earnings ratio than AVROBIO, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Editas Medicine has a beta of 2.02, indicating that its share price is 102% more volatile than the S&P 500. Comparatively, AVROBIO has a beta of 1.63, indicating that its share price is 63% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and target prices for Editas Medicine and AVROBIO, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Editas Medicine	1	4	3	0	2.25
AVROBIO	0	2	5	0	2.71

Editas Medicine presently has a consensus price target of $38.6667, suggesting a potential upside of 31.30%. AVROBIO has a consensus price target of $32.1667, suggesting a potential upside of 129.76%. Given AVROBIO's stronger consensus rating and higher probable upside, analysts plainly believe AVROBIO is more favorable than Editas Medicine.

Institutional & Insider Ownership

87.2% of Editas Medicine shares are held by institutional investors. Comparatively, 81.2% of AVROBIO shares are held by institutional investors. 0.9% of Editas Medicine shares are held by insiders. Comparatively, 4.8% of AVROBIO shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

AVROBIO beats Editas Medicine on 8 of the 13 factors compared between the two stocks.

AVROBIO vs. Sorrento Therapeutics Stock

Sorrento Therapeutics (NASDAQ:SRNE) and AVROBIO (NASDAQ:AVRO) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, analyst recommendations, institutional ownership, earnings and dividends.

Profitability

This table compares Sorrento Therapeutics and AVROBIO's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sorrento Therapeutics	-760.19%	-490.67%	-38.31%
AVROBIO	N/A	-51.33%	-47.65%

Valuation and Earnings

This table compares Sorrento Therapeutics and AVROBIO's top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sorrento Therapeutics	$31.43 million	57.72	$-292,070,000.00	($2.12)	-3.25
AVROBIO	N/A	N/A	$-72,960,000.00	($2.66)	-5.26

AVROBIO has lower revenue, but higher earnings than Sorrento Therapeutics. AVROBIO is trading at a lower price-to-earnings ratio than Sorrento Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Sorrento Therapeutics has a beta of 2.61, indicating that its share price is 161% more volatile than the S&P 500. Comparatively, AVROBIO has a beta of 1.63, indicating that its share price is 63% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and target prices for Sorrento Therapeutics and AVROBIO, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sorrento Therapeutics	0	0	2	0	3.00
AVROBIO	0	2	5	0	2.71

Sorrento Therapeutics presently has a consensus price target of $27.00, suggesting a potential upside of 291.30%. AVROBIO has a consensus price target of $32.1667, suggesting a potential upside of 129.76%. Given Sorrento Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Sorrento Therapeutics is more favorable than AVROBIO.

Institutional & Insider Ownership

24.1% of Sorrento Therapeutics shares are held by institutional investors. Comparatively, 81.2% of AVROBIO shares are held by institutional investors. 3.4% of Sorrento Therapeutics shares are held by insiders. Comparatively, 4.8% of AVROBIO shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Sorrento Therapeutics beats AVROBIO on 7 of the 13 factors compared between the two stocks.

AVROBIO vs. Mesoblast Stock

Mesoblast (NASDAQ:MESO) and AVROBIO (NASDAQ:AVRO) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, analyst recommendations, institutional ownership, earnings and dividends.

Profitability

This table compares Mesoblast and AVROBIO's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Mesoblast	-242.38%	-15.49%	-11.36%
AVROBIO	N/A	-51.33%	-47.65%

Valuation and Earnings

This table compares Mesoblast and AVROBIO's top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mesoblast	$32.16 million	55.74	$-77,940,000.00	($0.74)	-20.65
AVROBIO	N/A	N/A	$-72,960,000.00	($2.66)	-5.26

AVROBIO has lower revenue, but higher earnings than Mesoblast. Mesoblast is trading at a lower price-to-earnings ratio than AVROBIO, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Mesoblast has a beta of 3.87, indicating that its share price is 287% more volatile than the S&P 500. Comparatively, AVROBIO has a beta of 1.63, indicating that its share price is 63% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and target prices for Mesoblast and AVROBIO, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mesoblast	0	1	4	0	2.80
AVROBIO	0	2	5	0	2.71

Mesoblast presently has a consensus price target of $15.85, suggesting a potential upside of 3.73%. AVROBIO has a consensus price target of $32.1667, suggesting a potential upside of 129.76%. Given AVROBIO's higher probable upside, analysts plainly believe AVROBIO is more favorable than Mesoblast.

Institutional & Insider Ownership

2.5% of Mesoblast shares are held by institutional investors. Comparatively, 81.2% of AVROBIO shares are held by institutional investors. 18.8% of Mesoblast shares are held by insiders. Comparatively, 4.8% of AVROBIO shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Mesoblast beats AVROBIO on 7 of the 13 factors compared between the two stocks.

AVROBIO vs. Atara Biotherapeutics Stock

Atara Biotherapeutics (NASDAQ:ATRA) and AVROBIO (NASDAQ:AVRO) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, analyst recommendations, institutional ownership, earnings and dividends.

Risk and Volatility

Atara Biotherapeutics has a beta of 2.26, indicating that its share price is 126% more volatile than the S&P 500. Comparatively, AVROBIO has a beta of 1.63, indicating that its share price is 63% more volatile than the S&P 500.

Profitability

This table compares Atara Biotherapeutics and AVROBIO's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Atara Biotherapeutics	N/A	-94.86%	-82.17%
AVROBIO	N/A	-51.33%	-47.65%

Institutional & Insider Ownership

98.3% of Atara Biotherapeutics shares are held by institutional investors. Comparatively, 81.2% of AVROBIO shares are held by institutional investors. 4.3% of Atara Biotherapeutics shares are held by insiders. Comparatively, 4.8% of AVROBIO shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Atara Biotherapeutics and AVROBIO's top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atara Biotherapeutics	N/A	N/A	$-290,980,000.00	($5.67)	-4.05
AVROBIO	N/A	N/A	$-72,960,000.00	($2.66)	-5.26

AVROBIO is trading at a lower price-to-earnings ratio than Atara Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and target prices for Atara Biotherapeutics and AVROBIO, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atara Biotherapeutics	0	1	8	0	2.89
AVROBIO	0	2	5	0	2.71

Atara Biotherapeutics presently has a consensus price target of $31.50, suggesting a potential upside of 37.02%. AVROBIO has a consensus price target of $32.1667, suggesting a potential upside of 129.76%. Given AVROBIO's higher probable upside, analysts plainly believe AVROBIO is more favorable than Atara Biotherapeutics.

Summary

AVROBIO beats Atara Biotherapeutics on 7 of the 11 factors compared between the two stocks.

AVROBIO vs. Scholar Rock Stock

Scholar Rock (NASDAQ:SRRK) and AVROBIO (NASDAQ:AVRO) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk and dividends.

Volatility and Risk

Scholar Rock has a beta of 0.68, indicating that its stock price is 32% less volatile than the S&P 500. Comparatively, AVROBIO has a beta of 1.63, indicating that its stock price is 63% more volatile than the S&P 500.

Profitability

This table compares Scholar Rock and AVROBIO's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Scholar Rock	-301.13%	-61.68%	-35.74%
AVROBIO	N/A	-51.33%	-47.65%

Institutional and Insider Ownership

66.3% of Scholar Rock shares are owned by institutional investors. Comparatively, 81.2% of AVROBIO shares are owned by institutional investors. 24.6% of Scholar Rock shares are owned by insiders. Comparatively, 4.8% of AVROBIO shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Scholar Rock and AVROBIO's top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scholar Rock	$20.49 million	73.39	$-51,000,000.00	($1.85)	-24.16
AVROBIO	N/A	N/A	$-72,960,000.00	($2.66)	-5.26

Scholar Rock has higher revenue and earnings than AVROBIO. Scholar Rock is trading at a lower price-to-earnings ratio than AVROBIO, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and price targets for Scholar Rock and AVROBIO, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scholar Rock	0	0	3	0	3.00
AVROBIO	0	2	5	0	2.71

Scholar Rock currently has a consensus target price of $46.00, indicating a potential upside of 2.91%. AVROBIO has a consensus target price of $32.1667, indicating a potential upside of 129.76%. Given AVROBIO's higher probable upside, analysts plainly believe AVROBIO is more favorable than Scholar Rock.

Summary

AVROBIO beats Scholar Rock on 7 of the 13 factors compared between the two stocks.

AVROBIO vs. Cortexyme Stock

Cortexyme (NASDAQ:CRTX) and AVROBIO (NASDAQ:AVRO) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk and dividends.

Volatility and Risk

Cortexyme has a beta of 1.38, indicating that its stock price is 38% more volatile than the S&P 500. Comparatively, AVROBIO has a beta of 1.63, indicating that its stock price is 63% more volatile than the S&P 500.

Profitability

This table compares Cortexyme and AVROBIO's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cortexyme	N/A	-37.78%	-35.24%
AVROBIO	N/A	-51.33%	-47.65%

Institutional and Insider Ownership

51.6% of Cortexyme shares are owned by institutional investors. Comparatively, 81.2% of AVROBIO shares are owned by institutional investors. 19.8% of Cortexyme shares are owned by insiders. Comparatively, 4.8% of AVROBIO shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Cortexyme and AVROBIO's top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cortexyme	N/A	N/A	$-36,980,000.00	($1.94)	-25.06
AVROBIO	N/A	N/A	$-72,960,000.00	($2.66)	-5.26

Cortexyme is trading at a lower price-to-earnings ratio than AVROBIO, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and price targets for Cortexyme and AVROBIO, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cortexyme	0	0	4	0	3.00
AVROBIO	0	2	5	0	2.71

Cortexyme currently has a consensus target price of $68.3333, indicating a potential upside of 40.57%. AVROBIO has a consensus target price of $32.1667, indicating a potential upside of 129.76%. Given AVROBIO's higher probable upside, analysts plainly believe AVROBIO is more favorable than Cortexyme.

Summary

Cortexyme beats AVROBIO on 6 of the 11 factors compared between the two stocks.